GlassScriptPhysician profile
An Thien Tang
NPI 1841357589
$1,091.36
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $181 · 2022: $173 · 2023: $22.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $173.78 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $152.35 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $149.66 | 2019-2020 | |
| Novo Nordisk INC | $116.09 | 2019-2022 | |
| Astellas Pharma US INC | $81.85 | 2019-2020 | |
| Pfizer INC. | $68.08 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $57.32 | 2019-2020 | |
| Lilly USA, LLC | $46.60 | 2019-2022 | |
| Glaxosmithkline, LLC. | $38.94 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.11 | 2019 | |
| Amgen INC. | $36.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $29.66 | 2019-2020 | |
| Abbvie INC. | $24.29 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.61 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strongbridge US INC. | $15.33 | 2020 | |
| Merck Sharp & Dohme LLC | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw An Thien Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.